Roche personalized investigational medicine shows survival benefit in advanced skin cancer
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that BRIM3, a Phase III clinical study of RG7204 (PLX4032), met its co-primary endpoints showing a significant survival benefit in people with previously untreated BRAF V600 mutation-positive metastatic melanoma.
Bayer and Regeneron start MYRROR Phase III Trial
- Details
- Category: Bayer
Bayer HealthCare and Regeneron Pharmaceuticals announced initiation of a new Phase III clinical trial in collaboration with the Singapore Eye Research Institute (SERI) investigating the efficacy and safety of VEGF Trap-Eye (aflibercept ophthalmic solution) in patients with choroidal neovascularisation (CNV) of the retina as a result of pathologic myopia.
Boehringer Ingelheim to Purchase Amgen's Fremont (California) Facility
- Details
- Category: Amgen
Amgen Inc. (Nasdaq: AMGN) and Boehringer Ingelheim have signed an agreement under which Boehringer Ingelheim will acquire Amgen's rights in and substantially all assets at Amgen's Fremont California development and manufacturing facility.
GlaxoSmithKline announces Q4 2010 legal charge
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) announced that it expects to record a legal charge for the fourth quarter of 2010 of £2.2 billion ($3.4 billion) (equating to an after tax cost of £1.8 billion).
European Commission Clears Acquisition of Genzyme Corporation by sanofi-aventis
- Details
- Category: Sanofi
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced that the European Commision has cleared sanofi-aventis' proposed acquisition of Genzyme Corporation unconditionally under EU merger control rules.
Boehringer Ingelheim and Eli Lilly and Company Announce Strategic Alliance
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced a global agreement to jointly develop and commercialize a portfolio of diabetes compounds currently in mid- and late-stage development.
Sandoz announces phase II clinical trial for biosimilar version of rituximab
- Details
- Category: Novartis
Sandoz announced that it has begun a phase II clinical trial in patients for biosimilar rituximab (Roche's Rituxan® / Mabthera®), a leading monoclonal antibody indicated in conditions including non-Hodgkin's lymphoma and rheumatoid arthritis.
More Pharma News ...
- GlaxoSmithKline and ChemoCentryx announce initiation of Phase III study of GSK'786
- New Bayer U.S. Innovation Center starts its operations
- People to Actively Manage Their Type 2 Diabetes
- Genzyme Financial Recovery Continues in Fourth Quarter
- Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse®
- Abbott Receives CE Mark Approval for World's First Drug Eluting Bioresorbable Vascular Scaffold
- Genzyme Statement on Discussions With Sanofi-Aventis